Microsoft Likely to Be a Metaverse 'Winner,' Bernstein Says
Microsoft(NASDAQ:MSFT)is likely to be one of the "big" winners in the metaverse, investment firm Bernstein noted, pointing out that the journey fromconcept to reality will be beneficial for software s
US STOCKS-Dow Closes Lower after Disappointing Bank Results
The Dow closed lower with a big drag from financial stocks as investors were disappointed by fourth quarter results from big U.S. banks, which cast a shadow over the earnings season kick-off.The Nasda
As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.The S&P 500 is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any
Ntegrator International: The communications network specialist secured an S$8.6 million contract extension from a regional telecom provider for pipe installation and maintenance works in eastern, northern and western Singapore. The Catalist-listed group said in a bourse filing on Wednesday (Dec 1) that this deal adds to its order book of S$65.9 million as at Jun 30, 2021. Shares of thinly-traded Ntegrator ended Wednesday unchanged at S$0.007, before the announcement.Trading halt: Bread specialist QAF has called for a trading halt on Thursday (Dec 2) morning, pending an announcement. Shares of the counter closed at S$0.875, up 1.7 per cent or S$0.015, on Wednesday (Dec 1).
After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more
$Atea Pharmaceuticals, Inc.$ 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc. 8.7% HIGHER; announced the su